Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 1999

View Archived Issues

Selected purine analogues tested as angiogenesis inhibitors

Vivus terminates agreement with Bio-Medic Institute

HMR grants Fujisawa option to license malononitrilamide compounds

Major clinical study demonstrates efficacy and safety of Aviron's intranasal flu vaccine

Epimmune receives notice of allowance for patent covering vaccine technology

Zadaxin triple therapy shows promising results in preclinical model of colorectal cancer

Avigen licenses AAV-factor IX technology from the Children's Hospital of Philadelphia

York Medical gives update on development of anti-EGF receptor MAb for cancer Rx/Dx

Oral hepatitis B plant vaccine begins clinical trials in U.S.

ABT-431: the first D1 agonist with demonstrated antiparkinsonian activity in patients

U.S. patent issues for Celgene's ADHD treatment

NeXstar begins enrolling patients in U.S. phase I trial of NX-211

Onconase/interferon combination exerts synergistic antitumor activity in vitro

Broad-spectrum antivirals with heterocyclic structure developed at BioChem Pharma

Agents for AIDS extracted from plant source

Tetrionics will supply 2ME2 for EntreMed's preclinical testing program

Insulin secretion enhancers under study at Lilly for use in conditions of impaired glucose disposal

Bristol-Myers Squibb patents new series of CDK inhibitors

Novel pyridazines from Kowa inhibit cytokine production

Antitumor spectrum of Sch-66336 determined in human tumor cloning assay

New integrin receptor antagonists in the Merck pipeline

KRP-197: new bladder-selective antimuscarinic agent in clinical trials for bladder dysfunction

Xenova sells MetaXen to Exelixis

Licensing opportunity from NIH: method of preventing or reducing ischemic injury of the heart

Planned Rhone-Poulenc/Hoechst merger moves forward on schedule

Potent, orally active AVP receptor antagonist increases urine output in rats

Satellite symposium on antiarrhythmics underlines particular promise of dronedarone

TT-232, a new somatostatin analogue, effective against neurogenic and non-neurogenic inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...